Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
TOYO SECURITIES, 28% Decrease in Ordinary Profit for the Last Fiscal Year, Current period performance is undisclosed.
8614 TOYO SECURITIES CO., LTD. 【J-GAAP】
Earnings ReportTOYO SECURITIES CO., LTD. <8614> [TSE Prime] announced its financial results after the market closed on April 28th (16:00). The consolidated ordinary profit for the fiscal year ending March 2025 decreased 27.9% from the previous period to 1.03 billion yen. Furthermore, the company did not disclose the performance outlook for the fiscal year ending March 2026.
At the same time, the company has left the annual dividend for the current term undetermined.
In the most recent three-month period, from January to March (4Q), the consolidated ordinary profit significantly dropped to 0.13 billion yen, a 79.8% decrease compared to the same period last year. The operating profit margin sharply declined from 18.9% in the same period last year to 4.0%.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar, 2023 | 8,341 | -2,167 | -1,660 | -2,955 | -37.2 | 2 | Apr 27, 2023 | J-GAAP |
Mar, 2024 | 12,023 | 1,153 | 1,437 | 1,305 | 16.4 | 10 | Apr 26, 2024 | J-GAAP |
Mar, 2025 | 11,289 | 694 | 1,036 | 2,653 | 34.5 | 50 | Apr 28, 2025 | J-GAAP |
YoY | -6.1% | -39.8% | -27.9% | +103.3% | +110.6% |
Full Year Results vs. Previous Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar, 2025 Guidance | 11,289 | 694 | 1,036 | 2,653 | 39.1 | 50 | Apr 17, 2025 | J-GAAP |
Mar, 2025 Results | 11,289 | 694 | 1,036 | 2,653 | 34.5 | 50 | Apr 28, 2025 | J-GAAP |
Revision Rate | 0.0% | 0.0% | 0.0% | 0.0% | -11.8% |
Current Period Guidance
H1 Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Apr - Sep, 2024 | 5,557 | 233 | 437 | 1,419 | 17.7 | - | Oct 30, 2024 | J-GAAP |
Apr - Sep, 2025 Guidance | ー | ー | ー | ー | - | - | Apr 28, 2025 | J-GAAP |
YoY | - | - | - | - | - |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar, 2024 | 12,023 | 1,153 | 1,437 | 1,305 | 16.4 | 10 | Apr 26, 2024 | J-GAAP |
Mar, 2025 | 11,289 | 694 | 1,036 | 2,653 | 34.5 | 50 | Apr 28, 2025 | J-GAAP |
Mar, 2026 Guidance | ー | ー | ー | ー | - | - | Apr 28, 2025 | J-GAAP |
YoY | - | - | - | - | - |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Jan - Mar, 2024 | 3,595 | 679 | 674 | 610 | 7.7 | 18.9 | Apr 26, 2024 | J-GAAP |
Apr - Jun, 2024 | 2,943 | 173 | 335 | 169 | 2.1 | 5.9 | Jul 31, 2024 | J-GAAP |
Jul - Sep, 2024 | 2,614 | 60 | 102 | 1,250 | 15.6 | 2.3 | Oct 30, 2024 | J-GAAP |
Oct - Dec, 2024 | 3,030 | 353 | 463 | 158 | 2.0 | 11.7 | Jan 30, 2025 | J-GAAP |
Jan - Mar, 2025 | 2,702 | 108 | 136 | 1,076 | 14.0 | 4.0 | Apr 28, 2025 | J-GAAP |
YoY | -24.8% | -84.1% | -79.8% | +76.4% | +82.6% |
Related Articles
Sumitomo Pharma, Last Fiscal Year Net Income Revised Upward by 48%
Kushim, Last Fiscal Year's Net Income Loss Narrows, Current period performance is undisclosed.
NIHON KOGYO, 2% Increase in Ordinary Profit for The Current Fiscal Year, Dividend Raised by 5 yen
TSURUYA, Last Fiscal Year Ordinary Profit Revised Downward by 11%, Dividend Revised down by 2 yen
Financial Products Group, First Half Ordinary Profit Decreases by 1%
ONO PHARMA, Last Fiscal Year Net Income Revised Downward by 14%
Lasertec, Jan-Mar (3Q) Ordinary Profit Decreases by 53%
HOKURIKU ELECTRICAL CONSTRUCTION, 9% Decrease in Ordinary Profit for The Current Fiscal Year
XEBIO, Last Fiscal Year Ordinary Profit Revised Upward by 21%, Dividend Revised Upward by 2.5 yen
ORIENTAL LAND, 7% Decrease in Ordinary Profit for The Current Fiscal Year